August 24, 2020 -- Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373, the company's SARS-CoV-2 vaccine candidate.
The phase II trial expands on the positive results from the phase I portion by including older adults aged 60-84 years of age as approximately 50% of the trial's population. NVX-CoV2373 is a stable, prefusion protein made using Novavax's nanoparticle technology and proprietary Matrix-M adjuvant.
The study is a randomized, placebo-controlled, blinded study that will assess the drug at two doses (5 and 25 µg) each with 50 µg of adjuvant. Approximately 1,500 healthy participants are expected to enroll in the trial at 40 sites in the U.S. and Australia.
Funding for the trial is provided by the Coalition of Epidemic Preparedness Innovations.